CV Lars Hornum 2017

Lars Hornum, Brinken 12,4360 KirkeEskilstrup;59180443 (private);30759191 (mobile);lrshrnm@gmail.com
Curriculum Vitae
Lars Hornum, PhD
Principal Scientistwith proven track record in research group management and project initiation.Fifteen
years of experience from Pharmaceutical Industry.Deep insightinto clinical development through
participation in coredevelopment teams in several projects.Longstandingexperience in evaluation of in-
licensingopportunities.Responsiblefor a number of external in vivo activities and research collaborations.
Experience highlights:
 Scientific coordinator of three clinical stageprojects
 Headed target evaluations teams in both inflammation and diabetes complicationsareas
 Participated in duediligenceof four external opportunities,and in three outlicensingprojects
 Identified causeof neutropenia induced by 1st generation mAb in phase1 trial,which led to design of 2nd
generation mAb without this effect (verified in clinic)
 Developed and introduced the firstfunctional target engagement assay in theinflammation portfolio of
Novo Nordisk
Skills
 Project generation
 Sourcing
 Internal projectgeneration
 Research strategy
 Indication selection
 Selection of animal models
 Research group management
 Publications
 Publication planningand writing
 25 publications,37 abstracts,2 patents
 Member of Novo Nordisk Ethical Review
Council for Animal Experiments
 Responsiblefor animal permits
 Responsiblefor isotopework in department
Further information:
 Experience – appendix 1
 Education,languages,IT and supervision –
appendix 2
 Publications –appendix 3
 Collaborations –appendix 4
 Personal information –appendix 5

 External collaborations
 Clinicians,academics and CROs
 Clinical trial design
 Mechanismof action trials
 Advisor interaction
 Regulatory interaction
 Filings
 Interaction with authorities
 Patent work
Job History Employed in Novo Nordisk A/S sinceMarch 1992:
Sep 2014 – Now: Chair of Target Evaluation Team (Diabetes Complications Research)
Jun 2015 – Jun 2016 Initiator and Biology Coordinator of Diabetic Nephropathy project
September 2014 Termination of Inflammation area in Novo Nordisk and transfer to Diabetes
Complications Pharmacology department
Apr 2014 – Sep 2014: Scientific Coordinator for anti-NKG2D (Crohn’s disease)
Dec 2010 – June 2016: Scientific Coordinator for anti-C5aR,2nd generation
(Systemic lupus erythematosus, rheumatoid arthritis,ulcerativecolitis)
Feb 2009 – Dec 2013: Initiator and Biology Coordinator of new inflammation project
Sep 2007 Appointed Principal scientist
Apr 2007 – Jun 2013: Scientific Coordinator for anti-C5aR,1st generation
(Systemic lupus erythematosus, rheumatoid arthritis)
Jan 2007 – Mar 2009: SourcingHead in Inflammation
Jan 2001: Permanent position as research scientist –ImmunoPharmacology
Apr 1996 – Jan 2001: Post-doc at Hagedorn Research Institute (Type 1 diabetes genetics)
Mar 1992 – Apr 1996: PhD student at Hagedorn Research Institute(Type 1 diabetes genetics)

Lars Hornum CV
Appendix 1: Experience and skills
Diabetes complications (sinceSeptember 2014)
 Chair of the Target Evaluation Team, responsiblefor generating new projects in the area through in-licensingand
in-houseideation
o Five new projects initiated,one in-licensingprogressed to post-due diligencestage
 Initiator and biology coordinator of project(terminated due to negative animal model data)
 Responsiblefor a number of external in vivo activities and a major research collaboration
Inflammation projects (2007-2014)
Anti-NKG2D (Apr 2014-Sep 2014)
 Member of development core team
 Revised research plan postphase2a
 Partof 2-person group designingMechanismof Action trial
 Responsiblefor filingof research partof phase2b IMPD
 Participated in pre-IND meeting with FDA (carcinogenicity assessment)
Inflammation project (Feb 2009 – December 2013)
 Headed project proposal
 Biology coordinator until transfer of projectto development in 2013
Anti-C5aR (1st gen.: Apr. 2007-Jun 2013; 2nd gen.: Dec 2010-Sep 2014)
 Member of development core teams
 Headed approval of ulcerativecolitisas3rd indication in 2013 and involved in design of mode of action trial
 Headed research planningof a non-interventional trial in systemic lupus erythematosus in collaboration with New
York University
 Mapped alternativeindications
 Developed and introduced the firstfunctional target engagement assay in theinflammation portfolio of Novo
Nordisk
 Identified population biomarkers for the rheumatoid arthritis indication
 Identified PD biomarkers
 Identified causeof neutropenia induced by 1st generation mAb, which lead to design of 2nd generation mAb
without this effect (verified in clinic)
 Responsiblefor filingof research partof IMPDs since2007
 Member of patent group and driver of patent application “Useof C5aR antagonists” (notinventor)
Sourcing (2006- Sep 2014)
 Member of sourcingteams throughout period
 Headed inflammation sourcingteamfor 2 years (Jan 2007 – May 2009)
 Participated in duediligenceof 4 external opportunities

Lars Hornum CV
Appendix 2: Education and supervision
Education
1996 PhD in molecular genetics from Hagedorn Research Instituteand University of Copenhagen
1991 MSc in molecular genetics at the Institute of Genetics, University of Copenhagen
Grants
2006 Instrumental for obtaininga 3 year JDRF Research Grant (PI: Dr Helle Markholst)
2004 Instrumental for obtaininga 2 year EFSD-JDRF-Novo Nordisk European Programme in Type 1 Diabetes
Research Grant (PI: Helle Markholst)
2001 Received a 3 year Advanced Postdoctoral Fellowship Award from JDRF (declined becausethe
department (Dr Helle Markholst) also received a 3 year EFSD/JDRF/NN Grant for the same purpose)
1998 2 year Postdoctoral Fellowship Award from JDFI
1996 2 year Postdoctoral Fellowship Award from JDFI
1992 PhD fellowship fromthe Danish Research Academy
Courses
2016 Novo Nordisk A/S course “Global Research Coordinator Programme”
2006 Novo Nordisk A/S “Basic patent course”
2006 Novo Nordisk A/S course “Project Management: Overview & tools”
2000 Novo Nordisk A/S course”Experimental Animals and Animal Experiments”
1999 ”Laboratory Animal Science” at the Royal Veterinary and Agricultural University,Denmark
1998 ”Positional Cloning.Fromcontig to gene” at Cold SpringHarbor Laboratory
1997 ”Cloning & analysis of largeDNA molecules” at Cold SpringHarbor Laboratory
Languages
Danish Native speaker
English Complete professional
IT
MS Office,GraphPad Prism,multipleNovo Nordisk systems
Supervision
PhD
Ulla Nøhr Andersen (October, 2007) “The roleof Gimap5 in T-cell death”. University of Copenhagen
Master of Science
Ulla Nøhr Andersen (September, 2003) “Characterization of the rat Ian4L1 promoter”. University of Copenhagen
Technicians
Tina Larsen (April,2004),Laboratory Technicians Project, ErhvervsakademietNordsjælland,Hillerød.
KirstineJacobi (June, 2003) Laboratory Technicians Project,Laborantskolen,Copenhagen.
Appendix 3: Publications

Lars Hornum CV
Publications
1. Atkinson, SM, Nansen A, Usher PA, Søndergaard B-C, MacKay C, Friedrichsen B,Chang C-C, Tang R, Skov S, Haase
C, and Hornum L (2015) “Anti-C5aR Monoclonal Antibody Treatment Ameliorates DiseaseActivity in Murine
Delayed-Type Hypersensitivity Arthritis”. Autoimmunity 48, 460-470
2. HolmkvistP, Roepstorff K, Uronen-Hansson H, Sandén C, Gudjonsson S, Patschan O,Grip O, Marsal J,
Schmidtchen A, Hornum L, ErjefältJS, Håkansson,K and Agace WW (2015) “A major population of mucosal
memory CD4+ T cells,coexpressingIL-18Rαand DR3, display innatelymphocyte functionality”. Mucosal
Immunology 8, 545-558
3. Andersson C, Wenander C, Usher P, Hebsgaard,Søndergaard B-C, Rønø B, Mackay C, Friederichsen B, ChangC,
Tang R, Hornum L (2014) “Rapid Onset Clinical and Mechanistic Effects of anti -C5aRTreatment in the Mouse
Collagen Induced Arthritis Model” Clin Exp Immunol 177,219-233.
4. Hermansen MLF, Hummelshøj L, Lundsgaard D, Hornum L, Keller P, Fleckner J, Fox B, Poulsen LK and Jacobsen S
(2012) “Increased serum beta2-microglobulin is associated with clinical and immunological markers of disease
activity in systemic lupus erythematosus patients” Lupus 21, 1098-1104
5. DalbergUN, HaaseC, Hornum L and MarkholstH (2011):“The BB rat” in “Immunoendocrinology: Scientific and
Clinical Aspects.Contemporary Endocrinology Part3” (Ed. Eisenbarth,GS), 183-197.
6. Hornum L, Lundsgaard and MarkholstH(2007): “PolyI:C induction of diabetes is controlled by Iddm4 in rats with a
full regulatory T-cell pool”Annals of the New York Academy of Sciences 1110, 65-72
7. Andersen, UN, Markholst,H and Hornum, L (2007):“Both Gimap5 and the diabetogenic BBDP alleleof Gimap5
induceapoptosis in Tcells “ International Immunology 19,447-453
8. Lundsgaard D, Lindebo TL, Hornum L, MarkholstH(2005): “In vivo control of diabetogenic T cells by regulatory
CD4+CD25+ T cells expressing Foxp3”Diabetes 54, 1040-1047
9. Andersen, UN, Markholst,H and Hornum, L (2004):“The anti-apoptotic gene Ian4l1 in the rat: Genomic
organization and promoter characterization “ Gene 34, 141-148
10. Hornum, L and Markholst,H (2004): “New autoimmune genes and the pathogenesis of type 1 diabetes” Current
Diabetes Reports 4, 135-142
11. Hornum, L, DeScipio,C, Markholst,H, Troutman, SA, Novak, S, Leif, J, Greiner, D, Mordes, JP, and Blankenhorn, EP
(2004) “Comparative Mappingof Rat Iddm4 to segments on HSA7 and MMU6” Mammalian Genome 15, 53 – 61
12. Pandarpurkar,M,Wilson-Fritch,L, Corvera, S, Markholst,H, Hornum, L, Greiner, DL, Mordes, JP, Rossini,AA,
Bortell, R (2003):“Ian4 is required for mitochondrial integrity and T cell survival” Proc.Natl.Acad. U.S.A. 100,
10,382-10,387
13. Hornum, L, Rømer J and Markholst,H (2002): “The diabetes-prone BB ratcarries a frameshiftmutation in Ian4 – a
positional candidateof Iddm1” Diabetes 51, 1972-1979
14. Hornum, L, Lundsgaard,D and Markholst,H(2001): “A F344 ratcongenic for BB rat derived diabetes susceptibility
loci Iddm1 and Iddm2” Mammalian Genome 12, 867-868
15. Hornum, L and Markholst,H (2000): “A sequence-Ready PAC Contig of a 550 kb Region on Rat Chromosome 4
Including the Diabetes Susceptibility Gene, Lyp” Genomics 69, 305-313
16. Rasmussen,SB, Sørensen, TF, Hansen, JB, Mandrup-Poulsen,T, Hornum, L, and Markholst,H (2000): “Functional
Rest Through Intensive Treatment with Insulin and PotassiumChannel Openers Preserves Residual -Cell Function
and Mass in Acutely Diabetic BB Rats” Hormone and Metabolic Research 32, 294-300
17. Hornum, L and Markholst,H (2000): “Comparative Mappingof the Human Homologue of the Rat Diabetes
Susceptibility Gene Lyp to a 1.3-Mb Segment on HSA7” Genomics. 65, 81-83
18. Hornum, L and Markholst,H (2000): “Mapping of Zyx codingfor zyxin in the ratand its exclusion as a candidate
gene for lymphopenia.” Cytogenetics and Cell Genetics. 88,310-311
19. Hornum, L and Markholst,H (1999): “A genetic map of the Lymphopenia region on rat chromosome 4.”
Transplantation Proceedings 31,1615-1617
20. Hornum, L, Rasmussen,SB and Markholst,H (1999):“Mapping of Caspase-2 in the rat and its exclusion as a
candidategene for Lymphopenia.” Mammalian Genome 10, 244-248

Lars Hornum CV
21. Tullin,S, Farris,P,Petersen, JS, Hornum, L, Jackerott, M, and Markholst,H(1997): A pronounced thymic B-cell
deficiency in the spontaneously diabetic and T-cell lymphopenic BB rat.” Journal of Immunology 158,5554-5559
22. Jackerott, M, Hornum, L, Andreasen, BE, and Markholst,H (1997): “Segregation of autoimmune type 1 diabetes in
a cross between diabetic BB and Brown Norway rats.” Journal of Autoimmunity 10,35-41
23. Hornum, L and Markholst,H (1996): "Mappingof the ratPtn gene to chromosome 4." Mammalian Genome 7,
923-924
24. Hornum, L, and Markholst,H (1995): "Mapping of the ratHoxa11 homeobox gene to chromosome 4" Mammalian
Genome 6, 559-560
25. Hornum, L, Jackerott, M, and Markholst,H (1995): "The rat T-cell lymphopenia resistancegene (Lyp) maps
between D4Mit 6 and Npy on RNO4" Mammalian Genome 6, 371-372
Theses
Hornum, L (1996):"The BB rat lymphopenia resistancegene. A positional cloningapproach"PhD thesis.University of
Copenhagen.
Hornum, L (1991):"Application of Drosophila Kc-cellsas an expression systemof heterologous proteins" MSc thesis.
University of Copenhagen.
Patent applications
WO2012117067 (filingdate1-MAR-2012) “New monovalent antagonistic/bivalentagonistic death receptor 3 antibody
that blocks bindingof death receptor 3 to tumour necrosis factor-likeligand 1A,useful for treating e.g. inflammatory
disease,Crohn's disease,rheumatoid arthritis”
WO2005001052 (filingdate7-JUN-2004 ) “Modulatingapoptosis in cellsto treat autoimmune diseases or neoplasia
comprises contactingthe cell with a compound that modulates the expression or activity of an Ian4,leucine-rich
protein of 130kD, hsp60,GRP78 or GRP94”

Lars Hornum CV
Appendix 4: Collaborations
Diabetic Complications
Professor Thomas W. Gardner, KelloggEye Center, Ann Arbor, Michigan,U.S.A.
Professor John S. Penn, VanderbiltUniversity,School of Medicine, Nashville,Tennessee, U.S.A.
Assistantprofessor Jeffrey M. Sundström, Penn State Health, Hershey, Pennsylvania,U.S.A.
Professor Troels Krarup Hansen,University of Aarhus,Institute for Clinical Medicine,Århus,Denmark
Professor Peter Rossing,Steno Diabetes Center, Gentofte, Denmark
Inflammation
Professor Søren Jacobsen, Danish National Hospital,Department of Rheumatology, Copenhagen, Denmark
Professor Henning Bliddal and Dr ElseMarieBartel,The Parker Institute, Frederiksberg, Denmark
Docent Louise Berg, Unit of Rheumatology, KarolinskaInstitutet, Stockholm, Sweden.
Dr Fiona McCann,The Kennedy Institute of Rheumatology, University of Oxford,Oxford, U.K.
Professor Thomas T. MacDonald,Centre for Immunology and Infectious Disease,Barts and the London School of
Medicineand Dentistry, London, U.K.
Professor Jill Buyon,associateprofessor H.Michael Belmont and associateprofessor RobertClancy,Departments of
Hospital for JointDiseases and Medicine,New York University,New York, U.S.A.
Professor Charles MacKay,Monash Immunology & Stem Cell Labs,Monash University, Melbourne, Australia
Dr Peter Whitfeld, G2 Therapies Ltd., Garvan Instituteof Medical Research,Darlinghurst,Australia
Appendix 5: Personal information
 Born 1965 in Denmark
 Married to Bella Marckmann,PhD, Assistantprofessor of sociology,University of Copenhagen
 Two children:Niels (15 y) and Peter (12 y)
 Leisure activities:Singing in a classical choir and songwriting

CV Lars Hornum 2017

Recommended

Recommended

More Related Content

What's hot

What's hot (19)

Viewers also liked

Viewers also liked (17)

Similar to CV Lars Hornum 2017

Similar to CV Lars Hornum 2017 (20)

CV Lars Hornum 2017